Did you know that one in eight women in the U.S. will be diagnosed with breast cancer in her lifetime? At this current rate 13 million breast cancer deaths around the world will occur in the next 25 years.
While certain factors affect prognosis (chance of recovery) and treatment options, research on the biology of cancer is necessary to answer the most basic questions about what is and what is not normal. The outcomes of basic research in cancer biology are often uncertain, which makes oncology funding from profit-driven sources a risky undertaking.
On December 19, 2015 the National Institutes of Health (NIH) received a nearly $2 billion increase in funding for FY16 by way of approval of the Omnibus Appropriations Bill. The bill provided for continued funding for the Department of Defense’s Breast Cancer Research Program. Despite the increase, the National Cancer Institute’s (NCI’s) budget falls $238 million short of the $5.5 billion the institute requested for the fiscal year 2017 budget. Federal funding helps but is simply not enough to develop the arsenal of tools and strategies needed for sharing and communicating about oncology research results. More help is needed to fight this battle!
Amber M. Reed, Sentry BioPharma Services’ Warehouse Supervisor, declares her commitment to be a “Pink Warrior” by participating in the 25th Anniversary Komen Central Indiana Race for the Cure® on Saturday, April 16, 2016 commencing at the historic Military Park in downtown Indianapolis, Indiana. Ms. Reed says, “I have lost my grandmother and great-grandmother to breast cancer. My grandmother was like a mother to me. Since her passing in 2006 I have pledged to do whatever I can to help in the research to find a cure for this awful disease. I have participated in either Relay for Life® or Race for the Cure® every year since. I love the fact that I work for a company that also shares my dedication in helping to find a cure for cancer. Together I believe we can make cancer a thing of the past.”
According to the race sponsor’s website, “the Susan G. Komen Race for the Cure® Series is the world’s largest and most successful education and fundraising event for breast cancer ever created. The event raises significant funds and awareness for the breast cancer movement, celebrates breast cancer survivorship and honors those who have lost their battle with the disease.
This race is unique in the fact that 100% of the net proceeds are allocated to our mission. Seventy-five percent of the net income stays in our community to help fund local programs offering breast health education and breast cancer screening and treatment. The remaining 25% of the net income supports the Susan G. Komen® Grants Program.
Sentry BioPharma Services supports Ms. Reed’s efforts and commits to helping raise public awareness of this important cause. The company pledges on-going help to vaccine manufacturers by offering reliable GMP warehousing and drug distribution services to eliminate variables in oncology clinical trials in hope of one day eradicating this deadly disease.